scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters

Vaccines and Vaccination Strategies for Older Adults

TL;DR: In this article, the benefits and limitations of vaccines for the older population (influenza, pneumococcal disease, herpes zoster, SARS-CoV-2), and briefly discusses the importance of other vaccines for this age group.
Book ChapterDOI

Viral-vectored vaccines against SARS-CoV-2

TL;DR: In this article , the authors discuss about the rapid COVID-19 vaccine development, in comparison to other vaccines against newly emerging diseases, with particular attention to the leading viral-vectored vaccines in the latest clinical trials.
Journal ArticleDOI

Hemorragia intracerebral fatal asociada al síndrome de trombosis con trombocitopenia tras la vacuna ChAdOx1-S

TL;DR: In this paper , a case of intracerebral haemorrhage after ChAdOx1-S vaccination was reported and the patient developed a treatment resistant intracranial hypertension syndrome and she died three weeks later.
Posted ContentDOI

A SARS-CoV-2 peptide vaccine which elicits T-cell responses in mice but does not protect against infection or disease

TL;DR: Vulnerable BALB/c mice were vaccinated with peptides derived from the SARS-CoV-2 proteome designed to either elicit T-cell responses or B- cell responses against linear epitopes, and neither adjuvant group provided any protection against infection with the murine adapted virus Sars-Co V-2-MA10 or from disease following infection.
Posted ContentDOI

Quantifying the impact of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study

TL;DR: England's delayed second dose vaccination strategy was informed by early real-world vaccine effectiveness data and a careful assessment of the trade-offs in the context of limited vaccine supplies in a growing epidemic and shows that rapidly providing partial vaccine-induced protection to a larger proportion of the population was successful in reducing the burden of COVID-19 hospitalisations and deaths.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -